BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19145090)

  • 1. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
    Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
    Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in chronic myeloid leukemia (CML).
    Hochhaus A
    Onkologie; 2008 Nov; 31(11):576-8. PubMed ID: 19145088
    [No Abstract]   [Full Text] [Related]  

  • 3. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia].
    Wu W; Li JY; Shen YF; Cao XS; Qiu HR; Xu W
    Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):386-8. PubMed ID: 17637307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
    Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
    J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
    Wu W; Xue YQ; Wu YF; Pan JL; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):183-6. PubMed ID: 16792921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia.
    Pan J; Xue Y; Qiu H; Chen S; Zhang J; Wu Y; Shen J; Wang Y
    Cancer Genet Cytogenet; 2010 Dec; 203(2):333-40. PubMed ID: 21156255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.
    Xinh PT; Vu HA; Nghia H; Binh NT; Van Be T; Van Binh T; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jan; 164(2):122-7. PubMed ID: 16434314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.
    Vaz de Campos MG; Montesano FT; Rodrigues MM; Chauffaille Mde L
    Cancer Genet Cytogenet; 2007 Oct; 178(1):49-56. PubMed ID: 17889708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
    Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
    Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular genetics in chronic myeloid leukemia with variant Ph translocation].
    Wu W; Li JY; Zhu Y; Qiu HR; Pan JL; Xu W; Chen LJ; Shen YF; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):470-3. PubMed ID: 17680547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.
    Bennour A; Sennana H; Laatiri MA; Elloumi M; Khelif A; Saad A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):30-7. PubMed ID: 19737651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia.
    Yoong Y; VanDeWalker TJ; Carlson RO; Dewald GW; Tefferi A
    Eur J Haematol; 2005 Feb; 74(2):124-7. PubMed ID: 15654903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
    Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Deletions of derivative chromosome 9 in 138 patients with chronic myeloid leukemia].
    Wang L; Qian SX; Qiu HR; Wang R; Zhang SJ; Miao KR; Fan L; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):281-4. PubMed ID: 19379551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases.
    Albano F; Specchia G; Anelli L; Zagaria A; Storlazzi CT; Buquicchio C; Roberti MG; Liso V; Rocchi M
    Genes Chromosomes Cancer; 2003 Apr; 36(4):353-60. PubMed ID: 12619159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present.
    Batista DA; Hawkins A; Murphy KM; Griffin CA
    Cancer Genet Cytogenet; 2005 Dec; 163(2):164-7. PubMed ID: 16337861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.